Navigation LinksBiology NewsHealth NewsBiology TechnologyMedicine Technology


We're sorry, that page (http://www.bio-medicine.org/biology-products/mouse-anti-bovine-wc1-monoclonal-antibody--fitc-conjugated-from-abd-serotec-4404-1/;+health+history;+medical+history.html) was not found.

Search biology products mouse anti bovine wc1 monoclonal antibody fitc conjugated from abd serotec 4404 1 ;+health+history;+medical+history html at Google

Search biology products mouse anti bovine wc1 monoclonal antibody fitc conjugated from abd serotec 4404 1 ;+health+history;+medical+history html at Yahoo

Search biology products mouse anti bovine wc1 monoclonal antibody fitc conjugated from abd serotec 4404 1 ;+health+history;+medical+history html at Msn

Google
 
(Date:12/3/2009)In the 1980s, Harald zur Hausen and his co-workers discovered that specific types of human papillomavirus (HPV) cause cervical cancer. Scientists soon found out how these pathogens cause cells to dege
(Date:12/3/2009)PHILADELPHIA Now in its 32nd year, the CTRC-AACR San Antonio Breast Cancer Symposium continues to attract the best in breast cancer science and world leaders from industry and academia with the goal
(Date:12/3/2009)Forest dwellers must be included in the design of the upcoming forest deal at Copenhagen in order to avoid a humanitarian crisis, according to a scientist at the University of Leeds. , Writing today
Breaking Biology News(10 mins):Papillomavirus silences innate immune response 2CTRC-AACR San Antonio Breast Cancer Symposium continues to expand 2Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Cervical Cancer Vaccine Seems Safe 54788 1Cervical Cancer Vaccine Seems Safe 54788 2Cervical Cancer Vaccine Seems Safe 54788 3American Community Mutual Insurance Company 28ACMIC 29 Selects Corticon 54785 1American Community Mutual Insurance Company 28ACMIC 29 Selects Corticon 54785 2American Community Mutual Insurance Company 28ACMIC 29 Selects Corticon 54785 3American Community Mutual Insurance Company 28ACMIC 29 Selects Corticon 54785 4Reliv International Launches New Products and Business Tools at 21st International Conference 54781 1Reliv International Launches New Products and Business Tools at 21st International Conference 54781 2Reliv International Launches New Products and Business Tools at 21st International Conference 54781 3
(Date:12/4/2009)Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the
(Date:12/4/2009)Case Western Reserve University researchers, from the School of Medicine,s Department of Nutrition, discovered two new metabolic pathways by which products of lipid peroxidation and some drugs of abus
(Date:12/4/2009)Dental tourism is a phenomenon that was started by people that were looking for an alternative to the high price of dental work in the US, Canada, and other countries. In their search for lower priced
(Date:12/4/2009)Move a response to pressure from federal regulators to crack down on abuse of opioid medications , , FRIDAY, Dec. 4 (HealthDay News) -- The makers of 24 different prescription painkillers on F
(Date:12/4/2009)Research and surveillance urged for at-risk patient groups , , FRIDAY, Dec. 4 (HealthDay News) -- Some childhood cancers, particularly Ewing sarcomas and central nervous system tumors, carry t
Breaking Medicine News(10 mins):Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:Makers of Powerful Painkillers Present Safety Plans 2
DNA Polymerase I Large (Klenow) Fragment from New England Biolabs
T4 DNA Ligase (HC) from Invitrogen
Rat Anti-STENOTROPHOMONAS MALTOPHILIA Polyclonal Antibody, Unconjugated from AbD Serotec
... upgrade for Shimadzu Phoretix 2D, Expression and ...stical tools for comparative gel analysis studies ...Data base add on component Oracle data base plug...software). Supports advanced statistical tool se...
Biology Products:
Finnpipette Fixed Volume, 20ul
Pipetman F1000
Finnpipette Focus Fixed Volume, 1ul
Finnpipette Fixed Volume, 2ul
Medicine Products:
(Date:12/3/2009)SAN FRANCISCO, Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today anno
(Date:12/3/2009)NEW DELHI, India, Dec. 3 /PRNewswire-Asia/ -- Dr. Susan Jiang, M.D., Ph.D.,Chief Science Officer at Shenzhen Beike Biotechnology Co. Ltd.,( http://www.beikebiotech.com ), spoke at a conference on Hig
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Drug Discovery Technologies - A Global Update of Market Trends & Opportunities ,,
(Date:12/2/2009)LIBREVILLE, Gabon, December 2 , - "Bolstering Biodiversity in Africa: Everyone,s Problem and Heritage" , Coinciding with the International Year of Biodiversity, 2-3 June 2010 the,Gabonese Rep
Breaking Biology Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9Libreville International Conference 2-3 June 2010 2
(Date:12/4/2009)LAKE FOREST, Ill., Dec. 4 Hospira, Inc. (NYSE: HSP ), a leading global specialty pharmaceutical and medication delivery company, today announced the launch of its next-generation 50 mL and 100 mL V
(Date:12/4/2009)BILLERICA, Mass., Dec. 4 Axsun Technologies, Inc., a wholly-owned subsidiary of Volcano Corporation (Nasdaq: VOLC ), today announced the initial development and successful testing of a novel integra
(Date:12/4/2009)BETHESDA, Md., Dec. 4 Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the additional analysis of secondary end points of biochemical recurr
Breaking Medicine Technology:Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Expresso Fitness 28R 29 Announces 246M Series D Funding 54777 1Expresso Fitness 28R 29 Announces 246M Series D Funding 54777 2Expresso Fitness 28R 29 Announces 246M Series D Funding 54777 3What Texans Should Know about Cataract Surgery 54773 1What Texans Should Know about Cataract Surgery 54773 2What Texans Should Know about Cataract Surgery 54773 3TriLink BioTechnologies to Sponsor GIVING HUNGER THE BLUES a Benefit Concert to Help Alleviate Hunger in San Diego County 13615 1TriLink BioTechnologies to Sponsor GIVING HUNGER THE BLUES a Benefit Concert to Help Alleviate Hunger in San Diego County 13615 2TriLink BioTechnologies to Sponsor GIVING HUNGER THE BLUES a Benefit Concert to Help Alleviate Hunger in San Diego County 13615 3